reglab/housing_qa huggingface dataset:
LA Rev Stat § 40:1167.4 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1167.4. Establishment of the Electronic Health Records Loan Program

RS 1167.4 - Establishment of the Electronic Health Records Loan Program  A. The "Electronic Health Records Loan Program" is hereby created within the department.  B.(1) The secretary is hereby authorized to establish the Electronic Health Records Loan Program utilizing such sums that are made available through any one or more of the following:  (a) Annual appropriation.  (b) A public/private partnership involving financial institutions.  (c) Any other method authorized by law.  (2) Such funding shall be utilized by the state to satisfy the federal match requirements of the loan program provisions of ARRA.  (3) All loan program funds shall be administered by the department pursuant to the provisions of this Subpart.  C. To the extent permitted by law, the debt service associated with loans made to eligible providers shall be serviced from funds received by such providers as enhanced reimbursements under ARRA.  D. The department shall assist the state in the preparation of a competitive grant application and any other required submissions to secure funding made available under the ARRA loan program provisions.  E. The secretary is authorized to enter into CEAs to facilitate with any entity access to the ARRA loan program funding and to make loans to eligible providers to provide for the acquisition and implementation of certified EHR technology by eligible providers, and where integrated, telemedicine technology.  F. To provide for the expansion and administration of LARHIX and other related matters, the secretary shall enter into a CEA with the Coalition, the terms of which shall govern the program's loans made available to rural hospitals, and with the secretary's approval, to other rural health care providers who have elected to partner with rural hospitals in the acquisition of certified EHR technology. For purposes of this Subsection and to the extent permitted by the ARRA, certified EHR technology will include telemedicine technology which such technology is fully integrated with the certified EHR technology acquired by the hospital.  G. The secretary may consult with the Louisiana Healthcare Quality Forum in administering this program.  Acts 2009, No. 489, §1, eff. July 1, 2009; Redesignated from R.S. 40:1299.97.4 by HCR 84 of 2015 R.S.
LA Rev Stat § 40:1168.1 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1168.1. Findings and purpose

RS 1168.1 - Findings and purpose  A. The legislature hereby finds and declares that, while specific definitions of the term vary, "evidence-based medicine" refers to the practice of medicine based upon evidence derived from research and in a manner in which the physician bases clinical decisions upon such evidence.  B. The purpose of this Subpart is to promote the practice of evidence-based medicine in Louisiana through the creation of a system which facilitates the collection and analysis of information on health effects, events, and outcomes associated with the use of medical marijuana by patients in this state.  Acts 2019, No. 207, §1.
LA Rev Stat § 40:1168.2 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1168.2. Definitions

RS 1168.2 - Definitions  For purposes of this Subpart, the following terms have the meaning ascribed to them in this Section:  (1) "Adverse event" means any incident relating to the use of a drug prescribed or recommended to a patient that may result in serious harm or injury to the patient or in the patient's death.  (2) "Board" means the Louisiana State Board of Medical Examiners.  (3) "Data system" means the system authorized and provided for in R.S. 40:1168.3.  (4) "Medical marijuana" means the therapeutic substance produced under the authority of and in accordance with R.S. 40:1046.  (5) "Physician" has the meaning ascribed in R.S. 37:1262.  Acts 2019, No. 207, §1.
LA Rev Stat § 40:1168.3 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1168.3. Data system; components; reporting; design in collaboration with medical schools; public records exception

RS 1168.3 - Data system; components; reporting; design in collaboration with medical schools; public records exception  A. The board may create and maintain an electronic system for the collection and analysis of clinical information associated with the use of medical marijuana by patients. The system shall include, at minimum, the following components:  (1)(a) A component for the collection of data concerning adverse events experienced by patients which are associated with the use of medical marijuana.  (b) The board shall design and administer the data system such that any of the following persons may report an adverse event:  (i) The patient.  (ii) A family member of the patient.  (iii) A physician who prescribes or recommends medical marijuana to a patient.  (iv) Any physician who treats a patient other than a physician who prescribes or recommends medical marijuana to the patient.  (2)(a) A component for the collection of data concerning health outcomes other than adverse events experienced by patients that are associated with the use of medical marijuana.  (b) The board shall design and administer the data system such that reporting of health outcomes is limited to physicians exclusively.  B. The board shall collaborate with the following institutions in designing and implementing the data system:  (1) The medical school of the Louisiana State University Health Sciences Center at New Orleans.  (2) The medical school of the Louisiana State University Health Sciences Center at Shreveport.  (3) The Tulane University School of Medicine.  (4) The Pennington Biomedical Research Center.  (5) The College of Nursing and Allied Health at Southern University and Agricultural and Mechanical College.  (6) The Xavier University of Louisiana College of Pharmacy.  C. Except in cases of disclosure of data authorized by R.S. 40:1168.4(B), all data in the data system shall be confidential and shall not be available for subpoena, nor shall such information be disclosed, discoverable, or compelled to be produced in any civil, criminal, administrative, or other proceeding. The data maintained in the data system shall not be subject to any public records request nor shall any such data be considered as a public record pursuant to R.S. 44:1 et seq.  Acts 2019, No. 207, §1.
LA Rev Stat § 40:1168.4 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1168.4. Protection of health information; limitations on data use

RS 1168.4 - Protection of health information; limitations on data use  A. The board shall maintain the data system in a secure environment which complies, at minimum, with all applicable federal laws and regulations providing for the protection of health information.  B.(1) The board may authorize and facilitate access to data in the system to an outside party only if that party seeks the data for use in a bona fide medical research effort which has been authorized by the institutional review board of the organization conducting the research.  (2) The board shall have exclusive authority to determine whether an activity qualifies as a bona fide medical research effort in accordance with Paragraph (1) of this Subsection.  (3) Any disclosure of data in the system shall be subject to the approval of the board.  Acts 2019, No. 207, §1.
LA Rev Stat § 40:1168.5 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1168.5. Funding sources authorized for data system

RS 1168.5 - Funding sources authorized for data system  The board is hereby authorized to receive and expend all funds as may be necessary to implement and maintain the data system. Such funds may include, without limitation, funds appropriated by the legislature, including any appropriation of federal funds; funding provided by contract or other agreement with a governmental entity; and any public or private donations, gifts, or grants from governmental sources, individuals, corporations, nonprofit organizations, or other business entities.  Acts 2019, No. 207, §1.
LA Rev Stat § 40:1168.6 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1168.6. Rulemaking

RS 1168.6 - Rulemaking  The board shall promulgate all such rules in accordance with the Administrative Procedure Act as are necessary to implement the provisions of this Subpart.  Acts 2019, No. 207, §1.
LA Rev Stat § 40:1169.1 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1169.1. Short title

RS 1169.1 - Short title  This Subpart shall be known and may be cited as the "Right To Try Act".  Acts 2014, No. 346, §1; Redesignated from R.S. 40:1300.421 by HCR 84 of 2015 R.S.
LA Rev Stat § 40:1169.2 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1169.2. Legislative findings

RS 1169.2 - Legislative findings  The Legislature of Louisiana hereby finds and declares the following:  (1) The process of approval for investigational drugs, biological products, and devices in the United States often takes many years.  (2) A patient who has a terminal illness does not have the luxury of waiting until an investigational drug, biological product, or device receives final approval from the United States Food and Drug Administration.  (3) The standards of the United States Food and Drug Administration for the use of investigational drugs, biological products, and devices may deny the benefits of potentially life-saving treatments or devices to terminally ill patients.  (4) A patient with a terminal illness has a fundamental right to attempt to preserve his own life by accessing available investigational drugs, biological products, and devices.  (5) Whether to use available investigational drugs, biological products, or devices is a decision that rightfully should be made by the patient with a terminal illness in consultation with his physician, and is not a decision to be made by the government.  Acts 2014, No. 346, §1; Redesignated from R.S. 40:1300.422 by HCR 84 of 2015 R.S.; Acts 2017, No. 292, §1.
LA Rev Stat § 40:1169.4 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1169.4. Availability of drugs, biological products, and devices; costs; insurance coverage

RS 1169.4 - Availability of drugs, biological products, and devices; costs; insurance coverage  A.(1) A manufacturer of an investigational drug, biological product, or device may make available such drug, product, or device to eligible patients in accordance with the provisions of this Section.  (2) Nothing in this Section shall be construed to require a manufacturer to make available any drug, product, or device.  B. A manufacturer may do any of the following:  (1) Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.  (2) Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.  C.(1) A health insurance issuer may choose to provide coverage for the cost of an investigational drug, biological product, or device.  (2) Nothing in this Section shall be construed to require a health insurance issuer to provide coverage for the cost of any investigational drug, biological product, or device.  Acts 2014, No. 346, §1; Redesignated from R.S. 40:1300.424 by HCR 84 of 2015 R.S.
LA Rev Stat § 40:1169.5 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1169.5. Limitation of liability; no cause of action created

RS 1169.5 - Limitation of liability; no cause of action created  A. Notwithstanding any provision of law to the contrary, a physician who prescribes an investigational drug, biological product, or device to an eligible patient pursuant to the provisions of this Subpart shall be immune from civil liability, including but not limited to any cause of action arising under R.S. 40:1231.1 et seq., for any adverse action, condition, or other outcome resulting from the patient's use of the investigational drug, biological product, or device.  B. Nothing in this Section shall be construed as creating a cause of action by or on behalf of any person against a manufacturer of an investigational drug, biological product, or device, or against any person or entity involved in the care of an eligible patient using the investigational drug, biological product, or device, for any harm done to the eligible patient resulting from the investigational drug, biological product, or device.  Acts 2014, No. 346, §1; Redesignated from R.S. 40:1300.425 by HCR 84 of 2015 R.S.; Acts 2016, No. 355, §1.
LA Rev Stat § 40:1169.6 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1169.6. Action against physician license prohibited

RS 1169.6 - Action against physician license prohibited  Notwithstanding any provision of law to the contrary, the Louisiana State Board of Medical Examiners shall not revoke, fail to renew, or take any other action against the license of a physician issued pursuant to the provisions of R.S. 37:1261, et seq. based solely upon the recommendation of the physician to an eligible patient regarding, or prescription for, or treatment with, an investigational drug, biological product, or device when such recommendation, prescription, or treatment is undertaken in strict conformance with the provisions of this Subpart.  Acts 2014, No. 346, §1; Redesignated from R.S. 40:1300.426 by HCR 84 of 2015 R.S.
LA Rev Stat § 40:1170.1 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1170.1. Legislative findings; declaration

RS 1170.1 - Legislative findings; declaration  A. The legislature hereby finds all of the following:  (1) A developmental, intellectual, or physical disability does not diminish a person's right to health care.  (2) The provisions of the Americans with Disabilities Act of 1990, as amended (42 U.S.C. 12101 et seq.), prohibit discrimination against persons with disabilities, yet many individuals with disabilities experience discrimination in accessing critical healthcare services.  (3) In some cases, persons with developmental, intellectual, or physical disabilities have been denied life-saving organ transplants based on beliefs or assumptions by healthcare providers that those persons are incapable of complying with post-transplant medical requirements, or that they lack adequate support systems to ensure compliance with those medical requirements.  (4) Although organ transplant centers must consider medical and psychosocial criteria when determining whether a patient is suitable to receive an organ transplant, transplant centers that participate in Medicare, Medicaid, and other federally funded programs are required to use patient selection criteria that result in a fair and nondiscriminatory distribution of organs.  B. The legislature hereby declares that Louisiana residents in need of organ transplants shall be entitled to an assurance that they will not encounter discrimination on the basis of a disability.  Acts 2019, No. 57, §3, eff. May 30, 2019.
LA Rev Stat § 40:1170.4 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1170.4. Enforcement; civil actions against covered entities; construction of Section

RS 1170.4 - Enforcement; civil actions against covered entities; construction of Section  A. Whenever an individual believes that a covered entity has violated or is violating any provision of R.S. 40:1170.3, the affected individual may commence a civil action for injunctive and other equitable relief against the covered entity for purposes of enforcing compliance with this Subpart. The action may be brought in the district court for the parish where the affected individual resides or resided or was denied the organ transplant or referral.  B. In an action brought under this Section, the court shall give the action priority on its docket and expedited review, and may grant injunctive or other equitable relief including by any of the following means:  (1) Requiring auxiliary aids or services to be made available for a qualified recipient.  (2) Requiring the modification of a policy, practice, or procedure of a covered entity.  (3) Requiring that facilities be made readily accessible to and usable by a qualified recipient.  C. Nothing in this Section is intended to limit or replace available remedies under the Americans with Disabilities Act of 1990, as amended (42 U.S.C. 12101 et seq.), or any other applicable law.  D. This Section shall not be construed as creating a right to compensatory or punitive damages against a covered entity.  Acts 2019, No. 57, §3, eff. May 30, 2019.
LA Rev Stat § 40:1171.1 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1171.1. Purpose; intent; insurance and R.S. 40:1157.3 not affected

RS 1171.1 - Purpose; intent; insurance and R.S. 40:1157.3 not affected  The legislature recognizes that confidentiality protection for information related to human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) is an essential public health measure. In order to retain the full trust and confidence of persons at risk, the state has an interest both in assuring that HIV test results are not improperly disclosed and in having clear and certain rules for the disclosure of such information. By providing additional protection for the confidentiality of HIV test results, the legislature intends to encourage the expansion of voluntary confidential testing for HIV so that individuals may come forward, learn their health status, make decisions regarding the appropriate treatment, and change behaviors that put them and others at risk of infection. The legislature also recognizes that confidentiality protections can limit the risk of discrimination and the harm to an individual's interest in privacy that unauthorized disclosure of HIV test results can cause. It is not the intent of the legislature to create any new right, right of action, or cause of action or eliminate any right, right of action, or cause of action existing under current law. It is further not the intent of the legislature that this Chapter repeal, amend, or in any way affect the provisions of R.S. 40:1157.3 relative to the ability of a physician or employee of a hospital who may become infected with HIV to test the blood of a patient without the patient's consent. It is the intent of the legislature that in the case of a person applying for or already insured under an insurance policy, who will be or has been the subject of a test to determine infection for HIV, all facets of insurers' practices in connection with HIV-related testing and HIV test results and all facets of other entities' and individuals' interactions with insurers relating to HIV-related testing or HIV test results shall be governed exclusively by Title 22 of the Louisiana Revised Statutes of 1950 and any regulations promulgated pursuant thereto by the commissioner of insurance who shall have the authority to promulgate such regulations.  Acts 1991, No. 1054, §1; Acts 2012, No. 600, §2, eff. June 7, 2012; Acts 2012, No. 759, §2, eff. June 12, 2012; Redesignated from R.S. 40:1300.11 by HCR 84 of 2015 R.S; Acts 2018, No. 206, §4.
LA Rev Stat § 40:1171.2 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1171.2. Definitions

RS 1171.2 - Definitions  As used in this Subpart, the following terms have the meaning ascribed in this Section unless the context clearly indicates otherwise:  (1) "Contact" is a sex-sharing or needle-sharing partner, a person who has had contact with blood or body fluids to which universal precautions apply through percutaneous inoculation or contact with an open wound, non-intact skin, or mucous membrane, or a person who has otherwise been exposed to an HIV-infected person in such a way that infection may have occurred as defined by the Louisiana Department of Health regulations based upon guidelines of the United States Centers for Disease Control and Prevention.  (2) "HIV-related test" is a test which is performed solely to diagnose infection with human immunodeficiency virus (HIV).  (3) "HIV test result" is the original document, or copy thereof, transmitted to the medical record from the laboratory or other testing site the result of an HIV-related test. The term shall not include any other note, notation, diagnosis, report, or other writing or document.  Acts 1991, No. 1054, §1; Acts 2007, No. 153, §1; Redesignated from R.S. 40:1300.12 by HCR 84 of 2015 R.S; Acts 2018, No. 206, §4.
LA Rev Stat § 40:1172 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1172. Redesignated to R.S. 40:1117.1 by HCR 84 of 2015 R.S.

RS 1172 - Redesignated to R.S. 40:1117.1 by HCR 84 of 2015 R.S.
LA Rev Stat § 40:1173 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1173. §§1173, 1174 Repealed by Acts 1958, No. 34, §2

RS 1173 - §§1173, 1174 Repealed by Acts 1958, No. 34, §2
LA Rev Stat § 40:1173.1 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1173.1. Findings; legislative intent

RS 1173.1 - Findings; legislative intent  A. The legislature hereby finds all of the following:  (1) As a result of rising healthcare costs, the shortage of health professionals and healthcare services in many areas of the state, and the concerns expressed by consumers, healthcare providers, third-party payers, and others involved with making informed decisions regarding healthcare services, treatment, and coverage, there is a need to have access to provider specific healthcare cost, quality, and outcome data on healthcare facilities, healthcare providers, and health plans as well as continued access to global patterns and trends in the availability, use, and charges for healthcare services and the associated health circumstances.  (2) Due to the rapidly expanding availability of and access to patient sensitive healthcare data, it is necessary to establish safeguards which ensure the level of protection of patient encounter data that Louisiana citizens deserve, and which protect the privacy of health information comprising data sets that are reported and disseminated to improve the population health of this state.  B. It is the intent of the legislature to improve transparency in prices and care quality measures by providing for the creation and maintenance of a useful and comprehensive health service information database that can be publicly accessed in a manner that ensures protection of individuals' confidential health information and respects providers of care.  Acts 1997, No. 622, §1, eff. July 3, 1997; Acts 2007, No. 410, §1; Acts 2008, No. 537, §1, eff. June 30, 2008; Acts 2014, No. 790, §1; Redesignated from R.S. 40:1300.111 by HCR 84 of 2015 R.S.; Acts 2015, No. 338, §1.
LA Rev Stat § 40:1173.2 (2021)
2021 Louisiana Laws|Revised Statutes|Title 40 - Public Health and Safety|§1173.2. Definitions

RS 1173.2 - Definitions  As used in this Subpart, the following terms have the meaning ascribed to them in this Section:  (1) "Confidential information" means at least one of the following:  (a) Patient-level data elements that could be used alone or in combination with other available data elements to identify a patient.  (b) Information requested that the department determines will be utilized for business or commercial purposes, including but not limited to market analysis and software development.  (c) Protected health information as defined in the HIPAA Privacy Rule, 45 CFR Part 164, and R.S. 29:762.  (2) "Department" means the Louisiana Department of Health.  (3) "HIPAA" means the Health Insurance Portability and Accountability Act, Pub. L. 104-191.  (4) "Secretary" means the secretary of the Louisiana Department of Health.  Acts 1997, No. 622, §1, eff. July 3, 1997; Acts 2007, No. 410, §1; Acts 2008, No. 537, §1, eff. June 30, 2008; Acts 2014, No. 790, §1; Redesignated from R.S. 40:1300.112 by HCR 84 of 2015 R.S.; Acts 2018, No. 206, §4.